{"name": "mitiglinide", "category": "drug", "content": "Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes. Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.   == Pharmacology == Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium KATP channels in pancreatic \u03b2 cells.   == Dosage == Mitiglinide is delivered in tablet form.   == References ==   == External links == Elixir Pharmaceuticals \u2014 website of the U.S. rights holder for mitiglinide."}